SCHEMBL5227723

SCHEMBL5227723

COc1ccc(NC(=O)c2cc(O[Si](C)(C)C(C)(C)C)ccc2N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.56
HDAC1 Q13547 3/20 0.56
RAF1 P04049 1/20 0.56
ARAF P10398 1/20 0.56
LMNA P02545 2/20 0.51
GAA P10253 1/20 0.51
TSHR P16473 1/20 0.51
NPC1 O15118 6/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
HSP90AA1 P07900 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
PAX8 Q06710 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519025 0.81 KDM4E (0.50) GAATSHRKMT2AMAPTPKM
SCHEMBL2573168 0.80 BRAF (0.59) BRAFHDAC1RAF1ARAFNPC1
SCHEMBL5228240 0.79 NR1H4 (0.62) LMNAGAATSHRNPC1MEN1
SCHEMBL5222453 0.78 RAF1 (0.60) BRAFHDAC1RAF1ARAFLMNA
SCHEMBL15920977 0.78 BRAF (0.60) BRAFHDAC1RAF1ARAFNPC1
SCHEMBL6211617 0.78 KDM4E (0.47) MEN1KMT2AMAPTPKM
SCHEMBL5222830 0.77 BRAF (0.59) BRAFHDAC1RAF1ARAFNPC1
SCHEMBL28469086 0.77 BRAF (0.60) BRAFHDAC1RAF1ARAFGAA
SCHEMBL10163630 0.76 FADS1 (0.54) GAANPC1KMT2ARAB9ASMN1; SMN2
SCHEMBL5226494 0.76 HDAC1 (0.57) HDAC1LMNAGAANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 BRAF 952/4885HDAC1 61/4885RAF1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.